BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

pharmanewsdaily- July 3, 2020 0

NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the ... Read More